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Abstract: There is growing evidence that the env genes of two or more human endogenous retroviruses (HERVs) of  
the W family are contributing to the inflammatory processes, and thus to the pathogenesis, of multiple sclerosis (MS).
Increasing understanding of the human endogenous retroviral locus, ERVWE1, and the putative multiple sclerosis   
associated retrovirus, or MSRV, and in particular of the HERV-W env  sequences associated with these, offers the   
potential of new lines of pharmacological research that might assist diagnosis, prognosis and therapy of multiple sclerosis.
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INTRODUCTION 
  Multiple sclerosis, or MS, has many of the features of an 
autoimmune disease, where the pathology involves an im-
mune reaction to the body’s own cells or tissues – or to put it 
another way the failure of the adaptive immune system to 
recognise self. Useful, but inconclusive, information has 
come from the study of Mendelian genetics [1, 2], mean-
while, although the aetiology of MS remains uncertain, the 
innate and adaptive inflammatory processes involved are 
becoming increasingly understood at cellular and molecular 
level [3, 4]. There is evidence of genetic contribution to the 
autoimmune diseases. The human extended Major Histo-
compatibility Complex, or xMHC, is a key genetic region 
with regard to the evolution, and expression, of our adaptive 
immunity, with 22% of its 421 genes believed to have im-
munoregulatory function, and various genes associated with 
auto-immunity [5]. There is also growing evidence that hu-
man endogenous retroviruses, or HERVs, have played an 
important role in the evolution of the xMHC, and it is likely 
that they continue to play an important role in its function 
and malfunction [1, 6, 7]. In addition we now know that 
HERVs and related genetic sequences have contributed to 
the evolution and structure of the human genome per se, with 
implications for human embryology and physiology [8]. The 
logical first step in a systematic approach to understanding 
this complex situation is to examine the nature of HERVs 
and their importance in the evolution, genetic structure and 
function of the human genome.
HUMAN ENDOGENOUS RETROVIRUSES 
  We are familiar with viruses as the causative agents of 
infectious diseases, but we also need to recognise that, from 
the evolutionary perspective, they are also capable of bring-
ing about genetic change in the germ lines of their hosts.
This is known as viral symbiogenesis and it has major evolu-
tionary potential [9]. Conceptually and mechanistically, this  
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differs from the more familiar concept of genetic change 
through mutation, although it is complementary rather than 
contradictory to the classical concepts of evolution through 
mutation and selection.
  Symbiosis is defined as the living together of different 
organisms. The partners in a symbiotic relationship are 
known as “symbionts” and the partnership, regardless of the 
level of the symbiosis, is known as the “holobiont”. While it 
includes mutualism, symbiosis also includes parasitism, 
where one partner benefits to the detriment of another, and 
commensalism, where a partner benefits without detriment to 
the other partner, or partners. In fact mutualism very often 
derives from parasitism, and over time the nature of the rela-
tionship can involve dynamic change, which will also be 
reflected in how natural selection operates. When symbiosis 
gives rise to evolutionary change in one or more of the part-
ners, it is known as symbiogenesis. Symbioses take place at 
various levels, depending on the precise nature of the inter-
action. In lichens, for example, it involves the sharing of 
metabolites between algae and fungi, so this is known as a 
metabolic symbiosis. Other symbioses, such as those of the 
cleaner stations on the ocean floor, involve the sharing of 
complex behavioural patterns between large fish and small 
cleaner fish and crustaceans. These are examples of mutual-
istic symbioses in which the partners bring pre-evolved   
abilities to the holobiontic partnership. In all such mutualistic 
partnerships, even where the symbionts still reproduce   
independently, selection must work to some degree at   
partnership level.
  Viral symbiosis can also work at various levels, for   
example through culling of host species gene pool as part of 
a mechanism known as “aggressive symbiosis” [10]. This is 
probably a feature of most, if not all, viral epidemics, and it 
becomes particularly important when viruses enter into a 
persistent strategy with their hosts after initial infection [11].
Viral persistence, for example in the rabbit myxomatosis 
plague, or in the present human pandemic of AIDS, changes 
the virus-host evolutionary dynamic, making it more likely 
that selection will operate to a significant degree at partner-
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tional, powerful evolutionary dynamic that has played an 
important role in the evolution of the human genome, and 
thus becomes an important consideration in the pathogenesis 
of disease. This is the process of endogenization, where the 
infecting retrovirus inserts its genome into the germline of 
the host. This pattern of “genetic symbiogenesis”, involving 
the fusion of the two genomes of former parasite and former 
host, gives rise to a novel holobiontic genome. Viruses be-
having selfishly within a germ line would threaten survival.
Thus selection, at this stage, must operate at the level of the 
holobiontic genome, selecting for sequences of former host 
or virus that enhance survival and selecting against former 
host or viral sequences that impair survival. This offers the 
potential for powerful, and relatively rapid, evolutionary 
change. To understand the contribution of viral symbiogene-
sis to the evolution of the human genome, we need to look 
more closely at the genetic structure of a retrovirus. 
THE GENOMIC ORGANISATION OF RETRO- 
VIRUSES 
  The basic retroviral genome comprises three genetic do-
mains, conventionally referred to as the genes, env, gag and 
pol, which code for a variety of proteins. (Fig. 1) For exam-
ple gag codes for the proteins necessary for viral assembly, 
including matrix and core shell proteins, pol codes for the 
enzymes necessary for viral replication, such as reverse tran-
scriptase, protease, ribonuclease and integrase, while env
codes for the surface and trans-membrane glycoproteins. In 
particular, the env-associated proteins are essential for the 
binding of virus to cell-surface membranes and they have 
been specifically associated with neurovirulence [12]. In
virus-host interactions, these same proteins give rise to host 
cell fusion and immunosuppression. Thus the viral genome 
is a holistically functional unit whose genes, and flanking 
regulatory regions, known as LTRs, are pre-evolved to ma-
nipulate key aspects of human immunity, physiology and 
genetics. Invading retroviruses will often endogenize the 
germ lines of their hosts again and again, with up to a thou-
sand or so different sites of integration randomly distributed 
throughout the chromosomes, each integration site offering 
the possibility of future symbiogenetic potential. In human 
terms, although many such insertions have been “switched 
off” by the policing action of selection, such has been the 
massive volume of viral insertions that a significant number 
have positively contributed to the virus-host union, adding 
novel genetic complexity to the evolving holobiontic ge-
nome.
Fig. (1). There are three genetic domains, flanked by the regulatory 
LTRs, or long terminal repeats. The gag domain codes for matrix and 
core shell proteins, the pol codes for reverse transcriptase, protease, 
ribonuclease and integrase, and the env codes for the surface   
and trans-membrane glycoproteins. The env of a HERV-W is also 
responsible for syncytiotrophoblast cell fusion in the human placenta 
–see Fig. (4).
  The human genome contains between 30-50 different 
HERV families, subdivided into some 200 different sub-
groups, most of which resulted in multiple integrations, and 
most of which originate from exogenous retroviral invasion 
during the pre-human phase of our evolutionary history. The 
families and subgroups are commonly characterised on the 
basis of the single-letter code for the amino acid complemen-
tary to the t-RNA primer binding site that initiates transcrip-
tion. Thus, for example, a HERV-K initiates transcription 
with lysine and HERV-W with tryptophan. Each family and 
subgroup is thought to represent an independent evolutionary 
lineage, which would imply that the ancestral human genome 
has been subject to a large series of independent retroviral 
colonisations. Although many of these unions took place 
during our mammalian ancestry, at least eight full length 
HERV-K proviruses are unique to humans having entered 
the human germ line after humans diverged from chimpan-
zees [13, 14].
  The symbiogenetic potential of such massive viral colo-
nisation of the human genome is likely to be major. How-
ever, if we further consider that viral lineages, in particular 
those where the viral genes and regulatory sequences are 
conserved within the flanking viral regulatory LTRs, retain 
much that is quintessentially viral in structure and behaviour, 
we have an additional potential for the genetic underpinning 
of disease. 
  These virus-related sequences amount to almost half the 
total human DNA. (Fig. 2) HERVs and the retrotransposon
elements known as LINEs and SINEs (Fig. 3) have been 
incorporated into human embryology and day-to-day genetic 
chemistry and physiology [8, 15, 16]. Human endogenous 
retroviruses, and the retrotransposon elements, have also 
been discovered in the diseased cells and tissues of very 
many human diseases, and the majority of cancers and auto-
immune diseases [1, 17]. Research into the role of HERVs 
and retrotransposon elements in human evolution is at an 
early stage, and understanding of the potential role of 
HERVs and retrotransposons in this wide spectrum of dis-
ease is hampered by ignorance of the role they are playing in 
human development and normal physiology. This inevitably 
extrapolates to our understanding of the role of HERVs in 
Fig. (2). The “vertebrate” section contains the genes historically 
associated with coding for proteins, comprising exons separated by 
introns. The HERV section contains all of the HERV inserts, in-
cluding complete HERVs, defective HERVs and isolated LTRs. 
The LINEs and SINES (long interspersed and short interspersed 
repetitive elements) are classed as retro-transposons. The DNA 
transposons probably originated through DNA viral insertion. 
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MS, although there is increasing evidence that the HERV-W 
family is playing a significant role in the pathogenesis. It is 
illuminating to examine the specific HERV-W locus known 
as ERVWE1. 
THE ERVWE1 GENETIC LOCUS 
  Syncytin-1 is a viral protein that plays an essential role in 
the differentiation of the syncytiotrophoblast cells of the hu-
man placenta [18]. The ERVWE1 locus, a HERV-W inser-
tion that codes for syncytin-1, is located on human chromo-
some 7 (7q21.2). Its genetic structure is shown in Fig. (4), 
while a more detailed view of its regulatory region is shown 
in 4b [19]. It is clear that the locus contains a complete 
HERV-W, with gag, pol and env genes flanked by the regu-
latory LTRs. We also see that the viral genome is further 
flanked by the isolated LTRs of a second endogenous retro-
virus of the MaLR family. The locus is referred to as an ERV 
rather than HERV because humans share the locus with the 
great apes. It derives from an exogenous retrovirus (the for-
bear of the HERV-Ws) that invaded the primate genome 
between 20 and 30 million years ago, and while the gag and 
pol genes have been inactivated by deletions and stop 
codons, the env gene has been conserved in humans, chim-
panzees, gorillas and orang-utans. This env gene codes for 
the protein syncytin-1. It is promoted by the 5’HERV-W 
LTR, which has also been selectively conserved. An addi-
tional upstream regulatory component involves the con-
served 5’ MaLR LTR. So we have a viral gene within the 
structural unit of a viral genome, regulated to important de-
gree by two viral LTRs, which expresses a conserved viral 
protein that is essential to normal human reproduction.  
  ERVWE1 is far from unique in its viral contribution   
to human evolution and reproduction. We now know that 
there are at least seven additional endogenous retroviral   
elements that contribute to human reproduction, including
HERV-FRD, ERV-3, HERV-E.PTN, LTR10A, HERV-H7/ 
F(XA34), HERV-Fb1, and HERV-HML6-c14, [8, 10]. There 
is some evidence, albeit preliminary, that a number of differ-
ent HERV families may be contributing as yet unknown 
roles in the physiological function or cyto-chemical structure 
of the normal human brain [6, 8], as well as early evidence 
that HERVs may contribute to diseases involving the central 
nervous system [1]. There are two additional considerations 
of holobiontic viral integration that need to be grasped.
Fig. (3). Incomplete HERVs are derived from mutations affecting the various genetic domains and LTRs. There are two conflicting theories 
for the origins of the LINEs and SINEs. One theory posits an independent evolution within the genome. The other posits that they are break-
down products of endogenous retroviruses, which subsequently developed their own evolutionary trajectories. Functionally they interact with 
one another, so should be considered as related groups. 
Fig. (4). This genetic structure of the ERVWE1 locus contains a complete HERV-W, with its three genes gag, pol and env, together with the 
flanking LTRs. Whereas the gag and pol genes have been silenced by mutations, the env gene has been conserved by selection. The env gene 
promoter is contained within the HERV-W 5’LTR, with the relevant genetic sequence also conserved. There is an intron insert between the 
gag and 5’LTR. The upstream regulation of the env gene is complex, including the MaLR 5’LTR and the non-viral regulatory region deline-
ated in the figure. (After Gimenez J. and Mallet F. [19]) 
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Where a specific HERV has inserted many times into differ-
ent chromosomes, and where one or more of its insertions 
have become conserved for an essential genetic function, 
selection is likely to exert a “policing” control on the un-
wanted expression of closely homologous genetic sequences 
from other insertion sites, which might otherwise give rise to 
dysregulation of the conserved role. This is further compli-
cated by the fact that viral sequences, even if truncated or 
silenced by stop codons, may be capable of expression and 
even the unstopping of stop codons, through recombination 
between related HERVs [1, 20], although such mechanisms 
have yet to be confirmed in humans. There is an intriguing, 
though as yet tentative, suggestion that recombination of 
normally silenced HERVs and sequences might play a role in 
disease [21, 22].
THE MS-ASSOCIATED RETROVIRUS 
  In 1997, reporting for a collaboration of Swiss, French 
and British scientists, Perron described the isolation, and 
partial molecular identification, of novel retrovirus particles 
from cell cultures of the leptomeninges, choroid plexus, and 
peripheral blood B lymphocytes of MS patients. They also 
found related genetic sequences in the CSF and cell-free 
plasma of non-treated patients but not from matched controls 
[23]. They named the virus the MS-associated retrovirus, or 
MSRV. The authors were uncertain whether they were deal-
ing with an exogenous, infectious retrovirus or a replication 
competent, virion-producing HERV. Subsequently MSRV 
genetic sequences were found to share a close homology 
with the HERV-W endogenous family, and MSRV was sub-
sequently regarded as the founder discovery of this endoge-
nous virus family [24]. Continuing uncertainty as to whether 
the virus was exogenous or endogenous led to the MS-
associated virus being relabelled the MSRV/HERV-W, but 
for convenience the virus will be referred to as MSRV in this 
text. In 2003 Nowak and Polish colleagues found MSRV pol
sequences in the serum and peripheral blood lymphocytes of 
patients with other neurological conditions as well as con-
trols [25]. These sequences appeared to be endogenous and 
widely dispersed through the chromosomes. Perron also con-
firmed that gag and env proteins encoded by the MSRV are 
expressed by normal cells in the central nervous system [26].
However, the expression of such proteins in neurones of 
normal subjects was modest in density and compatible with 
some physiological function. Meanwhile there was an accu-
mulation of gag-encoded protein in neurones within demye-
linated white matter in MS-affected brains, and prominent 
gag-encoded protein was found in endothelial cells within 
MS lesions from acute or actively demyelinating cases, a 
pattern that was not seen in controls.
  In Sardinian patients – Sardinia appears to suffer a rela-
tively high incidence of MS – the Italian researchers, Dolei 
et al., confirmed the detection of MSRV in the plasma of 
12.8% of healthy blood donors, meanwhile they found the 
virus in the plasma of all 39 MS patients tested, which in-
cluded 24 suffering a relapsing remitting course, 4 secon-
dary-progressive and the remainder newly diagnosed [27, 
28]. The differences between MS and control findings was 
highly significant (p > 0.000001). They also detected the 
virus in the CSF of 80.6% of MS patients compared to 40% 
in a small cohort of controls with other neurological dis-
eases, such as CNS vasculitis, trigeminal neuralgia, ALS and 
recurrent optic neuritis of unknown origins. Further analysis 
of the latter groups suggested that MRSV presence in blood 
tallied with the inflammatory nature of the diseases. On first 
presentation all MS patients had detectable virus in their 
plasma, and 50% had detectable virus in the CSF. MSRV 
env and pol RNA transcripts were also detected, albeit at low 
levels in normal human blood and brain, but these showed a 
20- to 25-fold increase in brain samples from MS patients.
Increasing CSF titres of the virus over time correlated with 
both duration of disease and disease severity as ranked by 
standard clinical diagnostic criteria. They also showed strong 
immunoreactivity for MSRV in specific MS lesions in brain 
when compared to controls, with intense staining for MSRV 
env  expression in chronically active MS lesions, where it 
was localised to microglia and astrocytes. A similarly intense 
staining for env expression was found within astrocytes at 
the plaque core.
  This work confirmed a possible association between MS 
and expression of the putative MSRV, but uncertainty con-
tinued as to whether the virus was playing a role in patho-
genesis, as opposed to a physiological reaction to the disease, 
or perhaps no more than an epiphenomenon associated with 
inflammatory processes per se.
MSRV/HERV-W – PATHOGENETIC OR PHYSIO-
LOGICAL? 
 Retroviral  env proteins are known to give rise to neuro-
toxicity through a variety of direct and indirect mechanisms, 
for example through inducing glial cells to produce neuro-
toxic chemicals. The latter can implicate cells involved with 
innate immunity, such as macrophages, microglia and astro-
cytes, or cells involved with adaptive immunity, such as T or 
B lymphocytes, all of which have been variously linked to 
the pathology of MS [4, 12]. Retroviral neuro-toxicity can 
also involve complex interactions between exogenous vi-
ruses and endogenous retroviruses and host genetic varia-
tions that control the expression of the latter [29]. In 1997, 
Ménard, reporting on behalf of a multi-centre group of 
French and UK colleagues, found significant correlation be-
tween glial cell toxicity and reverse transcriptase activity in 
monocyte/macrophage culture supernatants in MS patients 
when compared to controls [30]. In 2001 Perron and col-
leagues showed that inoculation of peripheral blood lympho-
cytes (PBLs) of healthy controls with MSRV virion particles 
led to a significant polyclonal activation of T cells following 
the pathogenetic pattern of a superantigen [31]. A hybrid 
animal model grafted with human lymphocytes and injected 
intraperitoneally with MSRV led to fatal brain haemor-
rhages, with evidence of systemic viraemia and cytokine 
activation in the MSRV-injected animals [32], a response 
compatible with a T-cell mediated immunopathogenicity 
[33]. In 2002, the Italian group examined a further 15 MS 
patients, who had not been treated with immunomodulatory 
drugs for at least 3 months before taking CSF samples [34].
Nine of the 15 had demonstrable MSRV in their CSF. While 
the EDSS disability score and MRI findings showed no   
significant difference between patients with or without the 
virus at onset, the virus-positive cohort suffered more relapses 
and succumbed to a more disabling course over three years 
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MSRV in CSF at clinical onset of the disease correlated with 
disability progression. A positive feedback loop affecting 
MSRV expression was subsequently reported by the same 
group, where viral release from peripheral blood mononu-
clear cells was stimulated by the cytokines interferon-  and 
TNF , both known to play a detrimental role in MS, whereas 
viral release was inhibited by interferon- , a therapy of 
proven efficacy in MS [35].
  In 2004, Antony presented the findings of an interna-
tional collaboration that included Canadian, US, French and 
UK scientists, demonstrating increased expression of HERV-
W-env encoded protein in the brains of MS patients as   
opposed to normal controls [36]. Western blot testing   
also showed that syncytin-1, the protein encoded by the 
ERVWE1 locus, showed a three-fold increase in expression 
in brain tissue from MS patients as compared to controls.
Syncytin-1 immuno-reactivity was also found in activated 
glial cells within acute MS lesions and these cells also 
showed inducible nitric oxide synthase (iNOS) immunoreac-
tivity, which suggested ongoing inflammation. Because as-
trocytes and microglia are important modulators of neuroin-
flammation, they looked further at syncytin-1 regulation 
within these cells and confirmed that it was selectively 
upregulated in astrocytes and microglia from individuals 
with MS, but not in other neural cells, including neurones 
and oligodendrocytes. These findings showed similarities 
with what had been demonstrated by the Italian researchers 
testing for MSRV. However, based on the HERV-W env 
sequences, as compared to other HERV-env  sequences in 
GenBank, the authors concluded that the env expressed in 
their experiments was syncytin-1 coded by the env gene of 
the ERVWE1 locus. Constructing a vector that would effi-
ciently express the same HERV-W-env sequence within 
cells, they infected cell cultures of foetal astrocytes and 
macrophages with the vector and looked for syncytin-1-
mediated induction of neuro-inflammatory genes and their 
products. Within 24 hours of vector infection, the proin-
flammatory cytokine IL-1  was significantly increased in 
both cell types compared to controls. Inducible iNOS, an-
other potent neurotoxin, was also increased in astrocytes but 
not in monocytes, meanwhile the anti-inflammatory cytokine 
IL-10, was not induced by the vector. This suggested that 
syncytin-1 expression in astrocytes and macrophages selec-
tively induced proinflammatory responses.
  Oligodendrocytes are the cells that produce myelin, and 
are the principal cell associated with the demyelination in-
volved in the pathogenesis of MS. When human oligoden-
drocytes were exposed to the conditioned medium from cul-
tures of human foetal astrocytes and monocytes, the medium 
from the syncytin-1-stimulated cultures proved to be highly 
toxic to the oligodendrocytes when compared to the medium 
from non-syncytin-1-stimulated controls. This toxicity in-
cluded a range of observed effects from retraction of cellular 
process to cellular death. On the basis that the toxicity was in 
part the result of redox reactants, such as nitric oxide, they 
looked at the potential benefit of scavenging redox reactants, 
using the polyphenolic antioxidant, ferulic acid, a non-
steroidal anti-inflammatory-based-antioxidant. When intro-
duced into the culture medium, this markedly reduced the 
lethality to the oligodendrocytes. The authors went on to 
demonstrate a similar neuro-toxicity related to implantation 
of the syncytin-1 vector into the brains of mice, confirming 
uptake and syncytin-1 expression in astrocytes, followed by 
a decrease in oligodendrocyte numbers, accompanied by 
neuro-behavioural dysfunction on performance testing. The 
latter also appeared to be improved by concomitant treatment 
with ferulic acid.
  By now the weight of evidence, from study of both 
MSRV and the ERVWE1 locus, suggested that two HERV-
Ws, and in particular their env genes, were likely to be im-
plicated in the neuroinflammation of MS, and perhaps even 
the pathogenesis. In 2007 Antony and colleagues attempted a 
comparative study of the pathogenetic effects of ERVWE1 
and MSRV [37]. The two viruses were known to be mem-
bers of the same HERV-W family, with the pol sequences 
sharing 92% of their genetic identity, making it difficult to 
differentiate between the viruses using conventional probes.
But the env sequences of ERVWE1 and MSRV had been 
reported by Mallet to share 81% identity [18], which might 
make differentiation easier. For example research into the 
genetic coding for the surface unit of the HERV-W envelope 
protein, a 293 amino acid fraction, led to the recognition of a 
variety of genetic “clones”, each coding for a different vari-
ant of ENV-SU, with possible differences in their pathoge-
netic potential. The clone described by Mallet as representa-
tive of MSRV env was based on the GenBank accession 
number AF331500. However, Antony and colleagues based 
their MSRV env sequences on another clone, with the Gen-
Bank accession number AF123882.
  When they compared post-mortem brain tissues from 
patients with MS to controls, they found significant increases 
in the detection, and expression, of ERVWE1 env in MS 
brains while finding no increase in detection or expression of 
the AF123882 clone. They also found marked differences in 
the expression of env-encoding RNA in plasma and CSF 
samples of both patients and controls between the two differ-
ent env sequences. Where ERVWE1 env was found in 84% 
and 62% of plasma samples from MS versus non-MS pa-
tients and from 64% and 75% of CSF samples from MS ver-
sus non-MS patients. Meanwhile the AF123882 clone was 
detected in just a few plasma samples and in none of the CSF 
samples of both MS patients and controls. The high inci-
dence of ERVWE1 expression in normal controls is not sur-
prising since research, as yet unpublished, by Larsson and 
colleagues in Sweden has shown dense expression of syn-
cytin-1 in normal brains [personal communication]. Al-
though the function of syncytin-1 in normal brains is cur-
rently unknown, its regulation is complex and this might 
allow for a distinct physiological role in the normal physiol-
ogy of astrocytes, other glia, neurones or other cells or tis-
sues within the central nervous system. Antony’s results con-
trast with the findings of the Italian group [30-35], but the 
MSRV env sequence employed by the two groups appears to 
differ. Laufer  et al., would subsequently show that the 
AF123882 MSRV env clone, taken as representative of 
MSRV in the Antony study, represented an incomplete env 
open reading frame [22]. Two years later, when Rolland   
et al. looked at the clone AF331500, which they regarded as 
the ENV-SU of the MSRV – the envelope fraction that inter-
acts with host cells – they found that it induced human 
monocytes to produce major inflammatory cytokines through 
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tion receptors of primary importance in innate immunity 
[38]. This same ENV-SU could also trigger a maturation 
process in human dendritic cells and endow dendritic cells 
with the capacity to support a Th1-like pattern of Th cell 
differentiation.
  Overviewing the main published findings of the different 
groups, it seems that while both MSRV and ERVWE1 are 
associated with MS, the two are distinctly different members 
of the HERV-W family and they show differential expres-
sion and detection in MS patients’ tissues, cells and plasma.
Both ERVWE1 env and MSRV env showed increased ex-
pression in the brains of MS patients when compared to con-
trols. However, some caution is necessary in the interpreta-
tion of cellular detection, since the genetic sequences of the 
two viruses share such a close homology it is currently im-
possible to differentiate between them [26]. Clearly, the de-
velopment of specific antibodies or primers capable of intra-
cellular differentiation would be a major step towards under-
standing their differential contribution towards pathogenesis.
An earlier study had suggested that raised levels of HERV-
W and HERV-K in MS brains were secondary to activation 
by cytokines such as TNF  [39]. In 2007, a cooperative 
study involving the Italian researchers and colleagues in 
Philadelphia, examined the regulation of ERVWE1 in astro-
cyte cell cultures, showing that cytokines known to play sig-
nificant roles in the inflammatory process of MS, such as 
TNF , interferon- , interleukin-1 and interleukin-6, activated 
the ERVWE1 promoter, while interferon- , the therapeutic 
drug of proven efficacy in acute relapsing pattern MS, was 
inhibitory [40]. In particular they showed that TNF  activa-
tion of the promoter worked through a subunit, known as 
p65, within the enhancer domain of the promoter. TNF  ac-
tivation was epigenetically abolished by siRNA directed 
against p65 – indicating a possible therapeutic/ pharmacol-
ogical target. They also excluded the possibility that in-
creased expression of syncytin-1 in MS was caused by muta-
tional change in the ERVWE1 promoter. This led them to 
assume that the increased expression of ERVWE1 was re-
lated to the inflammatory microenvironment, and specifically 
the activation of the promoter by proinflammatory cytokines.
Highlighting the marked similarity of cellular location, ex-
pression and potential neuro-toxicity of both MSRV and 
ERVWE1 in MS patients throughout a range of different 
studies in different research units, and demonstrating that, in 
astrocytes, the ERVWE1 promoter is activated and inhibited 
by the same cytokines, and interferon- , as shown earlier 
with MSRV, they concluded that both MSRV and ERVWE1 
are likely to be activated in vivo in MS patients. 
  The growing link between a HERV-W env gene and MS 
was highlighted when the Italian group – who had earlier 
confirmed a link between detection of MSRV in CSF on first 
presentation with eventual poorer prognosis – now showed 
that the measurable viral load of MSRV in the blood and 
cerebrospinal fluid of MS patients correlated closely with 
clinical activity score, stage and progression of MS. Blood 
levels of the virus fell below detection limits in the majority 
of a group of patients after three months of beta-interferon 
therapy, suggesting that plasma titre of MSRV might be use-
ful both in prognosis and response in patients undergoing 
medical therapy [41]. In 2007 further research by Antony   
et al., showed that syncytin-1 regulates neuroinflammation 
and its receptor expression in MS. In particular ASCT1, a 
receptor for syncytin-1 and a neutral amino acid transporter, 
was selectively suppressed in astrocytes in the brains of MS  
patients. This paper included important new research on   
cultured astrocytes and further evidence that epigenetic 
blocking of the action of syncytin-1-induced suppression of 
ASCT1, and thus the release of oligodendrocyte cytotoxins 
by astrocytes [42]. By now the weight of evidence was sug-
gesting that both MSRV and ERVWE1, and specifically 
their env sequences, were contributing to the pathogenesis of 
MS. Moreover, studies in several centres were also indicat-
ing possible targets for pharmacological intervention [35, 36, 
40-42].
  In a further study, Mameli and colleagues searched for a 
reliable means of differentiating MSRV env from syncytin-1 
sequences [43]. They examined twelve variants of MSRV 
env and eight variants of syncytin-1 sequences, comprising 
all those deemed suitable from GenBank as well as those 
detected experimentally in their own cohort under study.
From this exhaustive group, they discovered a 12-nucleotide 
insertion in the trans-membrane moiety of the MSRV env
gene, which was present in all twelve MSRV env variants 
they tested but was absent from all of the syncytin-1 variants.
Based on this newly-discovered insertion, they developed 
discriminatory real time PCR assays that could selectively 
amplify either MRSV env or syncytin-1. Previous data had 
shown that both MSRV and ERVWE1 were expressed in the 
brains of MS patients, while only MSRV was found in pe-
ripheral blood plasma, and was expressed by cultures of pe-
ripheral blood monocytes (PBMCs) in blood-positive indi-
viduals. Also, while syncytin-1 had been found intracellu-
larly and on the plasma membrane, it had not been detected 
extracellularly and its sequences were not expressed in the 
MSRV virus-like particles, which were visible on electron 
microscopy, and contained demonstrable reverse tran-
scriptase activity and all three HERV-W genes. This ap-
peared to fit with the fact that ERVWE1 was exclusively 
expressed at cellular level, as would be expected of endoge-
nous sequences, meanwhile MSRV sequences were also ex-
pressed extracellularly, as would be expected of circulating 
virions. Now, using their newly constructed PCR assay, 
Mameli and colleagues were able to compare and contrast 
the expressions of HERV-W generic env,  MRSV  env and 
ERVWE1 env (syncytin-1) expression in the plasma, in cul-
tured PBMCs and in the supernatant of the cultured cells, in 
four MS patients who had not yet been treated, in four MS 
patients who had been treated and in six healthy blood do-
nors acting as controls. The results, albeit in small numbers 
of patients, were striking. 
  The controls showed no expression of any of the three 
env sequences. The untreated MS patients showed high lev-
els of expression of MSRV env in all three test situations, 
with markedly reduced titre of expression in the treated MS 
patients. A similar, but much lower level of expression of 
generic HERV-W env sequences was seen in all of the MS 
patients. Meanwhile there was no measurable expression of 
ERVWE1 env (syncytin-1) in the plasma or culture super-
natant of any of the MS patients, and it was only expressed 
in very low titre in a single untreated MS patient within the 
PBMCs. The authors concluded that these patterns of env 
expression confirmed the link between MS and MSRV.366    Current Neuropharmacology, 2011, Vol. 9, No. 2 F. P. Ryan 
RE-EXAMINING THE BASICS 
  A consistent, and important, uncertainty revolves around 
the question whether the MSRV is an exogenous infectious 
virus or the expression of an endogenous virus, or endoge-
nous sequences. The finding of extracellular virion particles 
does not necessarily imply an exogenous virus, since virion 
particles have been reported in the expression of HERVs, 
although these do not usually contain complete viral ge-
nomes. In a more general sense, the widespread discovery of 
HERV expression in autoimmune diseases and cancer, and 
the specific instance of HERV-Ws in MS, highlights the 
need for a fundamental methodological approach to HERVs 
in disease. In 2009, a study by Laufer and colleagues pro-
vided a role model for such a basic approach in examining a 
large number of transcribed loci of HERV-W env sequences 
within the human genome, and aiming to clarify the MS-
related retrovirus env contribution [22]. Pavlíek and col-
leagues had already shown that the HERV-W family has 
inserted into roughly 650 positions dispersed throughout the 
human chromosomes [44]. More than half of these have been 
reduced to solitary LTRs, but some 280 elements have re-
tained genetic sequences, most of which have been rendered 
defective through the acquisition of stop codons, frameshift 
mutations and deletions. The only known completely intact 
and functional HERV-W env locus appears to be the estab-
lished ERVWE1, located at 7q21.2, which codes for the syn-
cytin-1 complete envelope protein important to placentation.
  Rolland had already reported that the MSRV surface unit 
env  sequence, AF331500, was significantly different from 
that of the env of ERVWE1, showing 87% sequence homol-
ogy [38]. Messenger RNA can be transcribed in vitro using 
reverse transcriptase to produce its complementary DNA 
sequence, which is known as cDNA. In the genomes of pe-
ripheral blood mononuclear cells (PBMCs) of MS patients 
and controls, Laufer et al., showed that almost 30% of the 
HERV-W env cDNAs extracted by this technique were the 
result of recombinations of HERV-W env  elements from 
different chromosomal integrations sites. In the authors’ 
opinion these recombinations were most likely to have been 
generated in vitro. But viral recombination, a quintessentially 
symbiogenetic pattern of evolution, is also known to occur in
vivo, for example in the origins of pandemic influenza, and, 
as indicated above, there have been suggestions of such re-
combination involving retroviruses in rodents and humans 
[1, 20, 21]. 
  By mapping HERV-W env  cDNA sequences from 
PBMCs of MS patients and healthy controls onto individual 
genomic HERV-W env elements, they identified seven tran-
scribed HERV-W env loci in these cells. They confirmed 
that one of these was the HERV-W env locus, ERVWE1, 
coding for the placental syncytin-1, which, as already de-
scribed by Antony, is transcribed in the mononuclear cells of 
both normal controls and patients with MS. They also 
showed that the sequence, AF123882, taken by Antony as 
representative of MSRV env, probably originates from a 
HERV-W env locus on chromosome 15 (15q21.3), and rep-
resents an incomplete or interrupted open reading frame.
They further showed that the other five transcribed HERV-
W loci also had various deletions and truncations of their 
genetic domains and LTRs. But among these they identified 
a second transcriptionally active HERV-W env element,   
located on the X chromosome (Xq22.3), which contained an 
almost complete env gene, its full ORF interrupted by just a 
single stop codon at amino acid codon position 39. The 
translatable env sequence from this locus would give rise to  
a truncated syncytin-like protein of 475 amino acids. The 
sequence, AF331500, regarded as the standard MSRV env 
surface unit, could be explained as a recombination of 
Xq22.3 and another defective HERV-W env, on chromo-
some 5. Putting it another way, the amino acid sequence of a 
recombinant MSRV env SU protein, the same ENV-SU 
shown by Rolland to have proinflammatory properties, and 
which was generated using the AF331500 MSRV env clone, 
appeared to be identical to the amino acid sequence of the 
HERV-W env protein that would be encoded by the Xq22.3 
HERV-W env gene.
  There was an additional inference. The stop codons in the 
two env sequences, AF331500 and Xq22.3, differed in a sin-
gle nucleotide. The elimination of the stop codon at position 
39 of the HERV-W env Xq22.3 would result in an uninter-
rupted full-length HERV-W env open reading frame capable 
of encoding a complete env protein that contained a signal 
peptide. This stop codon of HERV-W env  Xq22.3 might 
readily be unstopped by recombination with other HERV-W 
env elements, which were shown to contain the necessary 
triplet at the right place. Laufer et al., also showed that the 
monoclonal antibody, 6A2B2, which had been shown to de-
tect a HERV-W env antigen present in MS lesions, was now 
seen to be generated against a fragment of the Xq22.3 
HERV-W env sequence. These findings raised the possibility 
that the antigen detected in the plaques of brains affected by 
MS could be encoded by the Xq22.3 HERV-W env locus.
NEUROPHARMACOLOGICAL EXTRAPOLATIONS 
  It seems likely that one or more HERV-Ws, and in par-
ticular their env genes, are playing a significant role in the 
pathogenesis of MS. This does not necessarily imply that 
they are aetiological, but it does suggest that they are in-
volved in a complex inflammatory interplay with other as yet 
not fully understood factors, including genetic predisposi-
tion, perhaps extrinsic factors such as stress, or exogenous 
viruses, and cytokines such as TNF . The HERV research 
has reached the stage where it appears to offer potential new 
lines of neuro-pharmacological research. A single putatively 
complete virus, the MSRV, and three env genes , related to 
MSRV, the HERV-W discovered by Laufer et al., on chro-
mosome X (Xq22.3), and the HERV-W, also known as the 
ERVWE1 locus, found on chromosome 7 (7q21.2), are 
prime candidates for such study. If Laufer et al., are correct 
in their conclusions, the env of MSRV and the X located 
HERV-W may prove to be intrinsically the same, which 
might, after confirmation by further research, reduce the 
candidate env sequences to two. Moreover, if Mameli et al.,
are supported in their most recent findings, the env sequence 
of the MSRV has a key 12 nucleotide insert in its trans-
membrane moiety that might enable its discrimination from 
the env of the ERVWE1 virus in future research. The poten-
tial pharmacological extrapolations fall into two broad cate-
gories, diagnostic/ predictive and therapeutic. The following 
is intended just as a general guide and does not aim to be 
exhaustive.Human Endogenous Retroviruses in Multiple Sclerosis  Current Neuropharmacology, 2011, Vol. 9, No. 2    367
Diagnostic/ Predictive Extrapolations 
  Although the therapeutic options in MS have improved in 
recent years, currently there is no simple haematological 
diagnostic or prognostic assay that might assist clinicians in 
managing MS. Haematological assays of the MSRV has 
been associated with drug therapy outcomes and predictions 
of severity of disease and prognosis. Its reconstructed ge-
nomic organisation has recently been outlined by Mameli   
et al., [43] and a highly specific env gene trans-membrane 
sequence has been reported. Both the putative virus and its 
env gene sequences have been repeatedly extracted from the 
plasma, supernatant of cultured PBMCs and CSF of patients 
suffering from MS. In the recent Mameli paper, albeit   
in small numbers of patients, relative quantification of the 
levels of MSRV env sequences showed marked differences 
between untreated MS patients and controls. In addition, 
approximately 70% of patients with optic neuritis, a disease 
that can be prodromic to MS, were reported by the same 
authors to be MSRV-positive in blood and CSF [45],   
although a previous study appears to have come to the very 
opposite conclusions [46]. Previous studies by the Italian 
group have also shown a dramatic reduction in MSRV RNA 
load and response to treatment with beta-interferon. They 
have also shown statistically significant correlations between 
the MSRV RNA load in plasma, PBMCs and CSF in relation 
to the clinical stage of MS and, in particular, progression of 
disease, with the CSF data further extrapolated to six years 
of follow-up [47]. This would suggest that there is potential 
for preliminary testing of in vitro diagnostic and predictive 
assays, for blood and for CSF, that should include MSRV, 
the predicted complete ORF of Xq22.3 env and the known 
env of ERVWE1, with the aim, initially, of confirming the 
usefulness of the assays and then, if confirmed, leading to 
standardised research and clinical laboratory assays.
Therapeutic Extrapolations 
  The development of the same in vitro tests of blood and 
CSF might also extrapolate to response to treatment assays.
There is some evidence that titres of MSRV in particular 
might help in predicting patients liable to more severe dis-
ease and a more aggressive long term prognosis [34]. This, 
in turn, might thus prove useful at a time when multiple 
therapies are available. A range of different pathogenetic 
mechanisms, involving both innate and adaptive immunity, 
have been shown to underlie relapse and progression of MS, 
and it is possible that different therapies may work in differ-
ent ways to mitigate these mechanisms. At the same time the 
secondary-progressive pattern of disease has proved to be 
more aggressive and resistant to therapies, making new ap-
proaches urgent. In this situation an in vitro test system that 
helped to differentiate possible responders to different thera-
pies at the onset of diagnosis and treatment would be helpful.
This might, for example, assist in predicting those patients 
who will prove relatively refractory to single therapy, so that 
alternative or multiple therapy might be considered. Inocula-
tion of peripheral blood lymphocytes (PBLs) of healthy   
controls with MSRV virion particles led to a significant 
polyclonal activation of T cells following the pathogenetic 
pattern of a superantigen [31]. The hybrid animal model   
experiments [32], with their suggestion of T-cell mediated 
immunopathogenicity [33], merit further extrapolation as 
does the work on the pro-inflammatory properties of the 
AF331500 ENV-SU clone taken as representative of MSRV 
by Rolland et al., [38]. Such probing of innate and adaptive 
immune responses to MSRV in vitro could be extended to 
the three env sequences and include probing and correlating 
the effects of various known, and potentially new, therapeu-
tic agents. The putative link between outcome and MSRV in 
CSF on presentation [33, 34, 47], if confirmed, could be ex-
tended, for example in patients suffering a more aggressive 
course of disease, where levels before and after different 
therapies, perhaps including multiple therapies, might prove 
helpful in predicting outcomes. Another line of investigation 
that might be worth further extrapolation is the evidence for 
a positive feedback loop affecting MSRV expression, and 
viral release from peripheral blood mononuclear cells stimu-
lated by cytokines [33].
  The work by Johnston et al., linking cytokines, such as 
TNF , to raised levels of HERVs might also prove useful to 
pharmacologists looking for means of in vitro experiment 
[39]. The elegant in vitro work by Antony et al., [36] intro-
ducing an env-containing vector to cell cultures of foetal 
astrocytes, macrophages and oligodendrocytes, would appear 
also to offer a potential tool for assessment of the neuro-
inflammatory properties of the MSRV and the three env se-
quences, and might augment the existing armamentarium for 
testing existing and novel therapeutic compounds.
  The cooperative study of ERVWE1 regulation in astro-
cyte cell cultures, highlighting the role of cytokines, and 
inhibitory effect of beta-interferon, might also be worth ex-
trapolating in the same way to existing and novel therapeutic 
compounds [40]. In particular it would be interesting to look 
in more detail at the subunit, p65, within the enhancer do-
main of the promoter, including the epigenetic work with 
siRNA, noting that the authors drew attention to this as a 
possible therapeutic/ pharmacological target. Pharmacolo-
gists interested in this arena might also note the marked simi-
larity of cellular location, expression and potential neuro-
toxicity of both MSRV and ERVWE1 in MS patients in dif-
ferent studies, which might suggest that both HERV-W 
members are significantly activated in the cerebral lesions of 
MS patients. But they should also bear in mind the current 
difficulty in differentiating between the two closely related 
env sequences and expressed products within cells, so the 
possibility remains that the unwonted expression of MSRV 
(?Xq22.3) env might dysregulate a physiological function of 
ERVWE1 syncytin-1.
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